Arrowgrass Capital Partners (US)’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
$5.88M Hold
158,100
1.55% 22
2019
Q3
$5.39M Hold
158,100
0.4% 72
2019
Q2
$6.5M Hold
158,100
0.15% 169
2019
Q1
$6.37M Buy
+158,100
New +$6.33M 0.19% 156
2018
Q4
Sell
-2,951
Closed -$12.3M 293
2018
Q3
$12.3M Sell
2,951
-292,169
-99% -$11.2M 0.38% 77
2018
Q2
$10.2M Buy
+295,120
New +$10.1M 0.35% 79
2018
Q1
Sell
-17,075
Closed -$587K 393
2017
Q4
$587K Buy
17,075
+16,904
+9,885% +$576K 0.01% 455
2017
Q3
$578K Hold
171
﹤0.01% 517
2017
Q2
$544K Sell
171
-1,824
-91% -$57.5K ﹤0.01% 548
2017
Q1
$6.48M Buy
1,995
+859
+76% +$27.1K 0.07% 305
2016
Q4
$3.5M Buy
1,136
+556
+96% +$17K 0.04% 296
2016
Q3
$1.86M Sell
580
-912
-61% -$30.5K 0.02% 308
2016
Q2
$4.99M Sell
1,492
-205
-12% -$6.54K 0.05% 192
2016
Q1
$4.77M Sell
1,697
-1,981
-54% -$56.6K 0.06% 193
2015
Q4
$11.3M Sell
3,678
-389
-10% -$12.2K 0.14% 97
2015
Q3
$12.1M Buy
4,067
+1,289
+46% +$41.3K 0.23% 82
2015
Q2
$8.84M Buy
2,778
+1,722
+163% +$56.1K 0.13% 145
2015
Q1
$3.49M Buy
+1,056
New +$33.6K 0.05% 187

Other funds holding PFE

Arrowgrass Capital Partners (US)'s PFE Position: Q4 2019 in Review

Arrowgrass Capital Partners (US) increased its Pfizer (PFE) stake by 4.6% in Q4 2019, buying an estimated $234K and bringing the position to 149,660 shares worth $5.56M. The position accounts for 1.46% of the portfolio, ranked #25.

Arrowgrass Capital Partners (US) first reported a position in PFE in Q2 2014 and has held it in 17 quarters since. The position peaked at $41M in Q4 2015. 2,525 funds tracked by Wall St. Rank hold PFE as of Q4 2019.

  • Arrowgrass Capital Partners (US) held 149,660 shares of Pfizer worth $5.56M as of Q4 2019.
  • Arrowgrass Capital Partners (US) bought 6,575 Pfizer shares in Q4 2019, an estimated $234K.
  • Pfizer made up 1.46% of Arrowgrass Capital Partners (US)'s portfolio in Q4 2019, its #25 holding.
  • Arrowgrass Capital Partners (US) first reported a position in Pfizer in Q2 2014 and has held it in 17 quarters since.
  • Arrowgrass Capital Partners (US)'s Pfizer position peaked at $41M in Q4 2015.
  • 2,525 funds tracked by Wall St. Rank held Pfizer as of Q4 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2019, filed 14 Feb 2020.